-1752956459196.webp&w=3840&q=75)
2025 NOSCM | Upper GI Cancer: Esophageal and Gastric-New Developments
Overview
Dr. Thomas Reske highlighted upper GI cancer advances, noting a 46% OS benefit with adjuvant nivolumab (Checkmate 577) and strong survival with FLOT+nivolumab (Matterhorn). Trastuzumab deruxtecan cut progression risk by 30% (Destiny 04). Claudin, CAR T, and antibody-drug conjugates show promise.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Thomas Reske, MD, PhD, FACP, CMD, AGSF
Date of Release
July 20th, 2025
-1755988787553.webp&w=3840&q=75)
-1755988610269.webp&w=3840&q=75)